News
News from akampion
We are pleased to announce that akampion has further strengthened its senior team with the addition of two highly experienced consultants — Francina Agosti, PhD, a trained neuroscientist, and Almut Gebhard, MSc, a trained biologist.
This move further expands akampion’s core strength: senior-level strategic communications advisory in situations where communications become truly value-critical — including financings, key data readouts, strategic milestones, leadership transitions, and early company-building phases.
Our team combines strong scientific expertise with long-standing, hands-on experience inside leading biotech, pharma, and healthcare organizations, as well as healthcare trade media. We understand internal decision-making processes, market dynamics, and the realities management teams face under time and stakeholder pressure. Importantly, we have worked alongside boards, executives, and investors not only as external advisors, but as accountable in-house colleagues.
This background enables us to:
- advise management teams strategically — not just execute — helping them shape their corporate positioning, reputation, and sharpen equity stories to reach critical value inflection points;
- integrate scientific depth with capital markets, investor, pharma, and media perspectives to support sound and convincing communications;
- operate effectively at senior and board level, drawing on decades of real in-house biotech, pharma, and media experience;
- align the communication of scientific and medical progress with stakeholder expectations across private and public markets;
- monitor and analyze our clients´ peer groups – a key prerequisite for successful strategic communications; and
- anticipate risks early and navigate sensitive issues and crisis situations with credibility and foresight.
akampion’s core team
- Ines-Regina Buth, MA, CBA, Managing Partner – former in-house PR/IR roles at Schering (now Bayer), Micromet (now Amgen), and Lion bioscience
- Ludger Weß, PhD (molecular biology), Managing Partner – former senior editor at BioCentury and BioWorld
- Francina Agosti, PhD (neuroscience), Senior Consultant – experienced science writer with a strong background in journalism and PR
- Almut Gebhard, MSc (biology), Senior Consultant – former in-house PR roles at Novartis, Schering (now Bayer), Noxxon Pharma (now TME Pharma), and the German Cancer Society
Beyond our core team, we collaborate with a trusted international partner network spanning commercialization, business development, and clinical and product development — allowing us to support clients holistically with a clear focus on long-term value creation.
About akampion
Founded in 2006, akampion is one of Europe’s leading communications consultancies dedicated exclusively to life sciences. We provide senior-level strategic communications advisory at critical value inflection points, combining deep scientific expertise, capital markets experience, and in-house biotech, pharma, and media backgrounds.
akampion has successfully supported more than 250 transactions, including financings, IPOs, M&A, licensing and partnering deals, dual listings, and product and technology launches. Our track record includes BioNTech’s Series A financing (USD 270m), ImmunOs Therapeutics’ Series B (USD 74m), T-knife’s Series A (EUR 66m), the Micromet–Amgen acquisition, Curetis’ IPO on Euronext, as well as complex crisis communications for MediGene and Paion and international product launches for Heraeus Medical and Gedeon Richter.